In a recent study, relapsing/refractory AML patients received venetoclax administration in combination with low-dose Cytarabine or hypomethylating agents: of 11 IDH-mutated AML patients, 27% responded to this treatment, with 1 CR, 1 CRi and 1 with morphologic leukemia-free state [162]. The gene discussed is IDH1; the disease is acute myeloid leukemia.